IRB# 15989
KCP-330: A Phase 2-3 Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) versus Placebo in Patients with Advanced Unresectable Dedifferentiated Liposarcoma

IRB# 10529
SARCO24: A blanket protocol to study oral regorafenib in patients with refractory liposarcoma, osteogenic sarcoma, and Ewing/Ewing-like sarcomas

IRB# 15649
EZH-202: A Phase 2, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects with INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma

IRB# 16070
A Phase 1B Study of Ribociclib in Combination with Doxorubicin in Advanced Soft Tissue Sarcomas

IRB# 20087
GSK208467: Open-Label Multi-cohort Clinical Trial to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells, alone or in combination with other agents, in HLA-A2+ Participants with NY-ESO-1 and/or LAGE-1a Positive Solid Tumors

IRB# 19313
A Phase 3 Trial of Nirogacestat Versus Placebo in Adult Patients with Progressing Desmoid Tumors/Agressive Fibromatosis

IRB# 20969
New study coming soon

http://www.ohsu.edu/research/rda/so/knight.php
Localized Resectable

Other Soft Tissue Sarcoma
Primary tumor >5cm
Retroperitoneal Liposarcoma

IRB# 19942
A resistance training program to improve physical function in sarcoma survivors

IRB# 17895
Local injection of anti-cancer drugs using Presage’s CIVO™ device in soft tissue sarcoma patients undergoing surgery

IRB# 17190
A Phase 1B trial of eribulin and radiation for retroperitoneal liposarcoma

IRB# 18084
S1609 (DART)

IRB# 20946
Diffuse Tenosynovial Giant Cell Tumor
New study coming soon

SARCOMA SURVIVORS:

CROSS-DISEASE TRIALS:

IRB# 19991
EAY131 (MATCH)

IRB# 18094
S1609 (DART)

Key

Open for Enrollment
In Development
Enrollment on Hold

http://www.ohsu.edu/research/rda/so/knight.php